New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ARNA;VVUS;OREX From The Last 14 Days
Check below for free stories on ARNA;VVUS;OREX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:18 EDTOREXOrexigen receives new US patent related to NB32 intellectual property
Orexigen announced that the U.S. Patent and Trademark Office has issued a patent related to NB32, the Company's investigational medication being evaluated for weight loss. NB32 is a fixed-dose combination of naltrexone sustained release and bupropion SR. U.S. Patent No. 8,815,889 claims methods for treating insulin resistance using a composition including naltrexone and bupropion. The patent expires in 2024. If NB32 is approved for use in the United States, Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and Drug Administration. A counterpart application to this patent has issued in Europe and other international jurisdictions.
08:18 EDTARNAArena Pharmaceuticals' APD811 granted orphan drug status
Subscribe for More Information
August 31, 2014
14:04 EDTARNAWorldwide Business Research to hold a conference
Subscribe for More Information
August 29, 2014
11:04 EDTARNAArena pulmonary arterial hypertension treatment granted orphan designation
The FDA granted orphan designation to Arena Pharmaceuticals' treatment of pulmonary arterial hypertension, according to a post to the agency's site. Reference Link
August 25, 2014
07:03 EDTVVUSVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use